Outcomes with allogeneic stem cell transplant using cryopreserved versus fresh hematopoietic progenitor cell products.

Autor: Wan BA; Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada., Lindo L; Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada; Terry Fox Laboratory, BC Cancer Research Institute, Vancouver, British Columbia, Canada., Mourad YA; Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada; Leukemia/Bone Marrow Transplant Program of BC, Vancouver, British Columbia, Canada., Chung S; Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada; Leukemia/Bone Marrow Transplant Program of BC, Vancouver, British Columbia, Canada., Forrest D; Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada; Leukemia/Bone Marrow Transplant Program of BC, Vancouver, British Columbia, Canada., Kuchenbauer F; Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada; Leukemia/Bone Marrow Transplant Program of BC, Vancouver, British Columbia, Canada., Nantel S; Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada; Leukemia/Bone Marrow Transplant Program of BC, Vancouver, British Columbia, Canada., Narayanan S; Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada; Leukemia/Bone Marrow Transplant Program of BC, Vancouver, British Columbia, Canada., Nevill T; Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada; Leukemia/Bone Marrow Transplant Program of BC, Vancouver, British Columbia, Canada., Power M; Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada; Leukemia/Bone Marrow Transplant Program of BC, Vancouver, British Columbia, Canada., Rodrigo J; Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada; Leukemia/Bone Marrow Transplant Program of BC, Vancouver, British Columbia, Canada., Sanford D; Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada; Leukemia/Bone Marrow Transplant Program of BC, Vancouver, British Columbia, Canada., Song K; Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada; Leukemia/Bone Marrow Transplant Program of BC, Vancouver, British Columbia, Canada., Stubbins RJ; Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada; Leukemia/Bone Marrow Transplant Program of BC, Vancouver, British Columbia, Canada., Sutherland H; Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada; Leukemia/Bone Marrow Transplant Program of BC, Vancouver, British Columbia, Canada., Toze CL; Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada; Leukemia/Bone Marrow Transplant Program of BC, Vancouver, British Columbia, Canada., White J; Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada; Leukemia/Bone Marrow Transplant Program of BC, Vancouver, British Columbia, Canada., Roy C; Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada; Leukemia/Bone Marrow Transplant Program of BC, Vancouver, British Columbia, Canada., Hay KA; Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada; Terry Fox Laboratory, BC Cancer Research Institute, Vancouver, British Columbia, Canada; Leukemia/Bone Marrow Transplant Program of BC, Vancouver, British Columbia, Canada; Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada. Electronic address: kevin.hay@ucalgary.ca.

Publikováno v: Cytotherapy [Cytotherapy] 2024 Oct; Vol. 26 (10), pp. 1210-1216. Date of Electronic Publication: 2024 May 08.

Outcomes of Intermediate Risk Karyotype Acute Myeloid Leukemia in First Remission Undergoing Autologous Stem Cell Transplantation Compared With Allogeneic Stem Cell Transplantation and Chemotherapy Consolidation: A Retrospective, Propensity-score Adjusted Analysis.

Autor: Limvorapitak W; The Leukemia/BMT Program of British Columbia, Division of Hematology, Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada; Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Thammasat University, Pathumthani, Thailand., Barnett MJ; The Leukemia/BMT Program of British Columbia, Division of Hematology, Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada., Hogge DE; The Leukemia/BMT Program of British Columbia, Division of Hematology, Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada., Forrest DL; The Leukemia/BMT Program of British Columbia, Division of Hematology, Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada., Nevill TJ; The Leukemia/BMT Program of British Columbia, Division of Hematology, Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada., Narayanan S; The Leukemia/BMT Program of British Columbia, Division of Hematology, Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada., Power MM; The Leukemia/BMT Program of British Columbia, Division of Hematology, Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada., Nantel SH; The Leukemia/BMT Program of British Columbia, Division of Hematology, Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada., Broady R; The Leukemia/BMT Program of British Columbia, Division of Hematology, Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada., Song KW; The Leukemia/BMT Program of British Columbia, Division of Hematology, Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada., Toze CL; The Leukemia/BMT Program of British Columbia, Division of Hematology, Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada., Mourad YA; The Leukemia/BMT Program of British Columbia, Division of Hematology, Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada., Sutherland HJ; The Leukemia/BMT Program of British Columbia, Division of Hematology, Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada., Gerrie AS; The Leukemia/BMT Program of British Columbia, Division of Hematology, Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada., White J; The Leukemia/BMT Program of British Columbia, Division of Hematology, Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada., Sanford DS; The Leukemia/BMT Program of British Columbia, Division of Hematology, Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada. Electronic address: david.sanford@bccancer.bc.ca.

Publikováno v: Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2018 Nov; Vol. 18 (11), pp. e481-e491. Date of Electronic Publication: 2018 Jul 17.

Association Of Prothrombin G20210 Gene Polymorphism And Risk Of Thrombosis In B.Thalassemic Children In Egypt.

Autor: M., Hesham¹, Ali, A. S.¹, Abougabal, Shaimaa Mahmoud¹, Fawzy, Amal² a.fawzy25@yahoo.com, magdy, Hanem²

Publikováno v: Zagazig University Medical Journal. Mar2024, Vol. 30 Issue 2, p513-521. 9p.

Evidence-based guidelines for the use of tyrosine kinase inhibitors in adults with Philadelphia chromosome-positive or BCR-ABL-positive acute lymphoblastic leukemia: a Canadian consensus.

Autor: Couban S; Department of Medicine, Dalhousie University, Halifax, NS., Savoie L; University of Calgary, Calgary, AB., Mourad YA; Leukemia and Bone Marrow Transplant Program of British Columbia, University of British Columbia, Vancouver, BC., Leber B; McMaster University, Hamilton, ON., Minden M; Department of Medical Oncology, University Health Network, University of Toronto, Toronto, ON., Turner R; Cross Cancer Institute, Edmonton, AB., Palada V; University of Toronto, St Michael's Hospital, Toronto, ON., Shehata N; University of Toronto, St Michael's Hospital, Toronto, ON., Christofides A; Senior Medical Writer, Toronto, ON., Lachance S; Hospital Maisonneuve-Rosemont, University of Montreal, Montreal, QC.

Publikováno v: Current oncology (Toronto, Ont.) [Curr Oncol] 2014 Apr; Vol. 21 (2), pp. e265-309.

Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (<12 months).

Autor: Venner CP; The Vancouver Hospital and Health Science Center, British Columbia, Canada., Connors JM, Sutherland HJ, Shepherd JD, Hamata L, Mourad YA, Barnett MJ, Broady R, Forrest DL, Hogge DE, Nantel SH, Narayanan S, Nevill TJ, Nitta J, Power MM, Toze CL, Smith CA, Song KW

Publikováno v: Leukemia & lymphoma [Leuk Lymphoma] 2011 Jan; Vol. 52 (1), pp. 34-41. Date of Electronic Publication: 2010 Dec 06.